Evolution and transmission of drug resistant tuberculosis in a Russian population

The molecular mechanisms determining the transmissibility and prevalence of drug-resistant tuberculosis in a population were investigated through whole-genome sequencing of 1,000 prospectively obtained patient isolates from Russia. Two-thirds belonged to the Beijing lineage, which was dominated by two homogeneous clades. Multidrug-resistant (MDR) genotypes were found in 48% of isolates overall and in 87% of the major clades. The most common rpoB mutation was associated with fitness-compensatory mutations in rpoA or rpoC, and a new intragenic compensatory substitution was identified. The proportion of MDR cases with extensively drug-resistant (XDR) tuberculosis was 16% overall, with 65% of MDR isolates harboring eis mutations, selected by kanamycin therapy, which may drive the expansion of strains with enhanced virulence. The combination of drug resistance and compensatory mutations displayed by the major clades confers clinical resistance without compromising fitness and transmissibility, showing that, in addition to weaknesses in the tuberculosis control program, biological factors drive the persistence and spread of MDR and XDR tuberculosis in Russia and beyond.

[1]  Daniel J. Wilson,et al.  Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study , 2013, The Lancet. Infectious diseases.

[2]  M. Nei.  Molecular Evolutionary Genetics , 1987 .

[3]  I. Mokrousov,et al.  Mycobacterium tuberculosis Population in Northwestern Russia: An Update from Russian-EU/Latvian Border Region , 2012, PloS one.

[4]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[5]  Sébastien Rodrigue,et al.  Activation of the eis gene in a W-Beijing strain of Mycobacterium tuberculosis correlates with increased SigA levels and enhanced intracellular growth. , 2009, Microbiology.

[6]  S. Niemann,et al.  High Resolution Discrimination of Clinical Mycobacterium tuberculosis Complex Strains Based on Single Nucleotide Polymorphisms , 2012, PLoS ONE.

[7]  L. Via,et al.  Mutations in gidB Confer Low-Level Streptomycin Resistance in Mycobacterium tuberculosis , 2011, Antimicrobial Agents and Chemotherapy.

[8]  S. Borrell,et al.  Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  Stephen D. Bentley,et al.  Microevolution of extensively drug-resistant tuberculosis in Russia. , 2012, Genome research.

[10]  F. Drobniewski,et al.  Associations between Mycobacterium tuberculosis Strains and Phenotypes , 2010, Emerging infectious diseases.

[11]  Olga Ignatyeva,et al.  Survival of Civilian and Prisoner Drug-Sensitive, Multi- and Extensive Drug- Resistant Tuberculosis Cohorts Prospectively Followed in Russia , 2011, PloS one.

[12]  M. Pai,et al.  GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis , 2008, European Respiratory Journal.

[13]  B. Barrell,et al.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.

[14]  Ying Zhang,et al.  Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus , 1996, Nature Medicine.

[15]  Tim Brown,et al.  Silent Nucleotide Polymorphisms and a Phylogeny for Mycobacterium tuberculosis , 2004, Emerging infectious diseases.

[16]  Razvan Sultana,et al.  Genomic Analysis Identifies Targets of Convergent Positive Selection in Drug Resistant Mycobacterium tuberculosis , 2013, Nature Genetics.

[17]  Y. Balabanova,et al.  Survival of drug resistant tuberculosis patients in Lithuania: retrospective national cohort study , 2011, BMJ Open.

[18]  A. Zaha,et al.  Streptomycin Resistance and Lineage-Specific Polymorphisms in Mycobacterium tuberculosis gidB Gene , 2011, Journal of Clinical Microbiology.

[19]  Jukka Corander,et al.  Identifying Currents in the Gene Pool for Bacterial Populations Using an Integrative Approach , 2009, PLoS Comput. Biol..

[20]  Diarmaid Hughes,et al.  Antibiotic resistance and its cost: is it possible to reverse resistance? , 2010, Nature Reviews Microbiology.

[21]  Z. Udwadia.  MDR, XDR, TDR tuberculosis: ominous progression , 2012, Thorax.

[22]  L. Liljas,et al.  Fitness‐compensatory mutations in rifampicin‐resistant RNA polymerase , 2012, Molecular microbiology.

[23]  Marc Aumercier,et al.  EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator , 2003, Molecular microbiology.

[24]  T. Sterling,et al.  A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. , 2012, The Journal of antimicrobial chemotherapy.

[25]  N. Colegrave,et al.  Mutational neighbourhood and mutation supply rate constrain adaptation in Pseudomonas aeruginosa , 2010, Proceedings of the Royal Society B: Biological Sciences.

[26]  J. Bayona,et al.  Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis , 2010, The Lancet.

[27]  W. Bishai,et al.  Fluoroquinolones, tuberculosis, and resistance. , 2003, The Lancet. Infectious diseases.

[28]  Stefan Niemann,et al.  Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes , 2011 .

[29]  James J. Cai.  PGEToolbox: A Matlab toolbox for population genetics and evolution. , 2008, The Journal of heredity.

[30]  M G Reynolds,et al.  Compensatory evolution in rifampin-resistant Escherichia coli. , 2000, Genetics.

[31]  Ted Cohen,et al.  The effect of drug resistance on the fitness of Mycobacterium tuberculosis. , 2003, The Lancet. Infectious diseases.

[32]  Jukka Corander,et al.  Enhanced Bayesian modelling in BAPS software for learning genetic structures of populations , 2008, BMC Bioinformatics.

[33]  Kai Ye,et al.  Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..

[34]  Jukka Corander,et al.  Hierarchical and Spatially Explicit Clustering of DNA Sequences with BAPS Software , 2013, Molecular biology and evolution.

[35]  P. V. van Helden,et al.  Putative Compensatory Mutations in the rpoC Gene of Rifampin-Resistant Mycobacterium tuberculosis Are Associated with Ongoing Transmission , 2012, Antimicrobial Agents and Chemotherapy.

[36]  Stefan Niemann,et al.  Variable host-pathogen compatibility in Mycobacterium tuberculosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Telenti,et al.  Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis , 1993, The Lancet.

[38]  Thomas Ludwig,et al.  A fast program for maximum likelihood-based inference of large phylogenetic trees , 2004, SAC '04.

[39]  Thomas Ludwig,et al.  RAxML-III: a fast program for maximum likelihood-based inference of large phylogenetic trees , 2005, Bioinform..

[40]  M. Kruijshaar,et al.  Tuberculosis in the UK: Annual report on tuberculosis surveillance in the UK, 2009. , 2009 .

[41]  S. Cole,et al.  Effect of katG Mutations on the Virulence of Mycobacterium tuberculosis and the Implication for Transmission in Humans , 2002, Infection and Immunity.

[42]  S. Cole,et al.  The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis , 1992, Nature.

[43]  S. Svenson,et al.  Spread of Drug-Resistant Pulmonary Tuberculosis in Estonia , 2001, Journal of Clinical Microbiology.

[44]  Julian Parkhill,et al.  Bacterial epidemiology and biology - lessons from genome sequencing , 2011, Genome Biology.

[45]  P HAUDUROY,et al.  MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE. , 1963, Bulletin of the World Health Organization.

[46]  W. Jacobs,et al.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.

[47]  F. Schmidt.  Meta-Analysis , 2008 .

[48]  Ziheng Yang.  PAML 4: phylogenetic analysis by maximum likelihood. , 2007, Molecular biology and evolution.

[49]  Brian G. Williams,et al.  Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis , 2002, Science.

[50]  J. T. Crawford,et al.  ethA, inhA, and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis Isolates , 2003, Antimicrobial Agents and Chemotherapy.

[51]  B. Metchock,et al.  Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis , 2009, Proceedings of the National Academy of Sciences.

[52]  Q. Gao,et al.  Association between embB Codon 306 Mutations and Drug Resistance in Mycobacterium tuberculosis , 2007, Antimicrobial Agents and Chemotherapy.

[53]  Sang-Nae Cho,et al.  Mycobacterium tuberculosis Eis Regulates Autophagy, Inflammation, and Cell Death through Redox-dependent Signaling , 2010, PLoS pathogens.

[54]  E. Böttger,et al.  Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot , 1993, Molecular microbiology.

[55]  Y. Balabanova,et al.  Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[56]  E. Böttger,et al.  Tuberculosis: drug resistance, fitness, and strategies for global control , 2008, European Journal of Pediatrics.

[57]  Thomas M. Shinnick,et al.  Molecular Analysis of Cross-Resistance to Capreomycin, Kanamycin, Amikacin, and Viomycin in Mycobacterium tuberculosis , 2005, Antimicrobial Agents and Chemotherapy.

[58]  J. Musser,et al.  Molecular Genetic Analysis of Nucleotide Polymorphisms Associated with Ethambutol Resistance in Human Isolates ofMycobacterium tuberculosis , 2000, Antimicrobial Agents and Chemotherapy.

[59]  Julian Parkhill,et al.  Evolution of MRSA During Hospital Transmission and Intercontinental Spread , 2010, Science.

[60]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[61]  F. Drobniewski,et al.  Evaluation of MGIT 960-Based Antimicrobial Testing and Determination of Critical Concentrations of First- and Second-Line Antimicrobial Drugs with Drug-Resistant Clinical Strains of Mycobacterium tuberculosis , 2006, Journal of Clinical Microbiology.

[62]  Clifton E. Barry,et al.  Compensatory ahpC Gene Expression in Isoniazid-Resistant Mycobacterium tuberculosis , 1996, Science.

[63]  Y. Balabanova,et al.  Drug-resistant tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia. , 2005, JAMA.

[64]  D van Soolingen,et al.  Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology , 1997, Journal of clinical microbiology.

[65]  Dongfang Li,et al.  Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance , 2013, Nature Genetics.